Novo Nordisk A/S

NYSE:NVO

Drug Manufacturers - General

Healthcare
$39.43 -1.09%

-$0.48 today

Market cap
$173.82B
Beta
0.35
P/E (TTM)
10.2
EPS (TTM)
$27.45
Dividend yield
4.18%
52W Low $35.12High $74.38

Volume 16.12M

Average 16.05M

NVO Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Novo Nordisk A/SNYSE: NVO

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin declines year over year

Q2 FY2026 selling, general & admin of DKK 16.31B fell 13.5% year over year, behind the -9.7% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 23.4% from the prior quarter. Over 3 fiscal years it compounded at +11.5% a year.

Context

  • Selling, general & admin amounted to 22.7% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 16 analysts of DKK 80.88B (+15.1%) for the fiscal year ending Dec 2026, a step up from the +4.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
DKK 16.31B+23.4% QoQ
Last fiscal yearDec 2025
DKK 70.28B+4.3% YoY
LTMJun 2026
DKK 64.84B-9.7% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-13.5%+7.9%+21.4 pp
1 year+4.3%+15.1%+10.8 pp
3-year CAGR+11.5%+7.5%-4.0 pp
5-year CAGR+6.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

DKK · from the income statement

Latest · FY2025
70.28B DKK
Year-over-year change
+4.3%
4-year CAGR
+14.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How NVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -9.7% is the 9th highest of 10, against a peer median of +8.7%.
  • Selling, general & admin amounts to 19.7% of revenue for NVO, versus a peer median of 21.5%.
NVO Competitors
Selling, General & Admin for NVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 64.84B DKK-9.7%+11.5%19.7%
JNJJohnson & JohnsonLTM Sep 2026$25.5B USD+11.0%+5.4%25.7%
AZNAstraZeneca PLCLTM Sep 2026$20.52B USD+0.5%+4.5%33.0%
ABBVAbbVie Inc.LTM Sep 2026$15.19B USD+8.7%-2.8%23.0%
PFEPfizer Inc.LTM Jun 2026$13.72B USD-1.7%+0.3%21.5%
LLYEli Lilly and CompanyLTM Jun 2026$12.24B USD+25.6%+22.3%15.4%
MRKMerck & Co., Inc.LTM Jun 2026$10.39B USD+10.8%+3.5%15.7%
SNYSanofiLTM Jun 2026€9.82B EUR+9.8%+5.4%20.1%
GSKGSK plcLTM Jun 2026£9.2B GBP-13.8%+2.8%27.7%
AMGNAmgen Inc.LTM Jun 2026$7B USD+1.8%+9.2%18.4%
Peer median (excluding NVO) —+8.7%+4.5%21.5%

Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

DKK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue140.8B176.95B232.26B290.4B309.06B
Cost of Revenue23.66B28.45B35.77B44.52B58.79B
Gross Profit117.14B148.51B196.5B245.88B250.28B
Gross Margin83.2%83.9%84.6%84.7%81.0%
Research & Development17.77B24.05B32.44B48.06B52.04B
Selling, General & Admin41.06B50.68B61.6B67.38B70.28B
Operating Expenses58.5B73.7B93.92B117.54B122.62B
Depreciation & Amortization6.03B7.36B9.41B19.11B21.98B
EBITDA65.39B76.8B114.63B147.94B156.73B
EBITDA Margin46.4%43.4%49.4%50.9%50.7%
Operating Income58.64B74.81B102.57B128.34B127.66B
Operating Margin41.7%42.3%44.2%44.2%41.3%
Interest Income231M239M1.07B1.84B1.27B
Interest Expense289M378M542M1.64B4.21B
Other Income / Expenses436M(5.75B)2.1B(1.15B)2.88B
Income Before Tax59.08B69.06B104.67B127.19B130.54B
Pre-Tax Margin42.0%39.0%45.1%43.8%42.2%
Income Tax Expense11.32B13.54B20.99B26.2B28.11B
Net Income47.76B55.53B83.68B100.99B102.43B
Net Margin33.9%31.4%36.0%34.8%33.1%
EPS (Basic)10.4012.2618.6722.6723.06
EPS (Diluted)10.3712.2218.6222.6323.03
Weighted Avg Shares4.59B4.53B4.48B4.45B4.45B
Weighted Avg Shares (Diluted)4.61B4.54B4.49B4.46B4.45B

Novo Nordisk A/S

NYSE:NVO

Intrinsic Alpha fair value

Locked

Current Price

$39.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.